<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972204</url>
  </required_header>
  <id_info>
    <org_study_id>ART-2013-01</org_study_id>
    <nct_id>NCT01972204</nct_id>
  </id_info>
  <brief_title>Intensive Instruction on the Use of Aricept</brief_title>
  <official_title>A Study About the Impact of Intensive Instruction on the Use of Aricept and the Reasons for Discontinuation in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirai Iryo Research Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirai Iryo Research Center, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the influence of the instruction on the use of
      Aricept with educational brochure on the 48-week medication persistence and to assess the
      reasons for discontinuation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the influence of the instruction on the use of Aricept with educational brochure
      comparing to the ordinary instruction on the 48-week medication persistence and to assess the
      reasons for discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Medication Continuation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of Participants who Continue the Medication for 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons for Discontinuation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Reasons for discontinuation of the Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Medication Discontinuation Due to Change to Alicept or Generics</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of Participants who descontinue the Clinical Trial Medication due to Change to Alicept (not for clinical trial) or Generics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Week 2, 12, 24, 48</time_frame>
    <description>Adverse Events for each arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Alzheimer's Type Dementia</condition>
  <arm_group>
    <arm_group_label>Intensive adherence instruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive adherence instruction</intervention_name>
    <description>Instruction with educational brochure</description>
    <arm_group_label>Intensive adherence instruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Instruction as per usual practice</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic evidence of probable Alzheimer's type Dementia consistent with DSM-IV.

          -  Written informed consent will be obtained from subject (if possible) or from the
             subject's legal guardian or other representative (according to Japanese regulations as
             appropriate) prior to beginning screening activities.

          -  Patients having caregivers who submit written consent for cooperative involvement in
             this study, can provide patients' information necessary for this study, assist
             treatment compliance, and escort patients on required visits to study institution.

          -  Outpatients in their own home.

        Exclusion Criteria:

          -  Patients treated with donepezil, galantamine, rivastigmine in 4 weeks immediately
             before enrollment.

          -  Known hypersensitivity to donepezil or piperidine derivatives.

          -  Involvement in any other investigational drug clinical trail during the preceding 12
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsumasa Kamei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Fujisawa Tokushukai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>February 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 17, 2019</last_update_submitted>
  <last_update_submitted_qc>February 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mirai Iryo Research Center, Inc.</investigator_affiliation>
    <investigator_full_name>Tetsumasa Kamei</investigator_full_name>
    <investigator_title>Hospital Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT01972204/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intensive Adherence Instruction</title>
          <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intensive Adherence Instruction</title>
          <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.7" spread="7.23"/>
                    <measurement group_id="B2" value="80.2" spread="6.99"/>
                    <measurement group_id="B3" value="79.9" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatmnent for alzheimer's disease before study</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Medication Continuation</title>
        <description>Number of Participants who Continue the Medication for 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Adherence Instruction</title>
            <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medication Continuation</title>
          <description>Number of Participants who Continue the Medication for 48 weeks</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Discontinuation</title>
        <description>Reasons for discontinuation of the Medication</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Adherence Instruction</title>
            <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Discontinuation</title>
          <description>Reasons for discontinuation of the Medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pysician's decision</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participant's wish</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caretaker's wish</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Medication Discontinuation Due to Change to Alicept or Generics</title>
        <description>Number of Participants who descontinue the Clinical Trial Medication due to Change to Alicept (not for clinical trial) or Generics</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Adherence Instruction</title>
            <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medication Discontinuation Due to Change to Alicept or Generics</title>
          <description>Number of Participants who descontinue the Clinical Trial Medication due to Change to Alicept (not for clinical trial) or Generics</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse Events for each arm</description>
        <time_frame>Week 2, 12, 24, 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Adherence Instruction</title>
            <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse Events for each arm</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intensive Adherence Instruction</title>
          <description>Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
Intensive adherence instruction: Instruction with educational brochure</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
Control: Instruction as per usual practice</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tomoko Machida (Director)</name_or_title>
      <organization>Mirai Iryo Research Center</organization>
      <phone>81-3-3263-4801</phone>
      <email>machida@mirai-iryo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

